Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help (GERN)

Core Insights - Geron Corporation (GERN) has completed five full quarters since the launch of Rytelo (imetelstat), but the launch is not showing strong growth [1] Company Performance - The performance of Rytelo (imetelstat) since its launch has not been robust, indicating potential challenges in market acceptance or competition [1] Analyst Perspective - The article reflects the author's opinion on GERN and its stock performance, emphasizing the importance of monitoring events such as trial results and regulatory approvals in the biotech sector [1]